Primary prevention. Colors correspond to Class of Recommendation in Table 1. ABI indicates ankle-brachial index; apoB, apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CHD, coronary heart disease; HIV, human immunodeficiency virus; hs-CRP, high-sensitivity C-reactive protein; LDL-C, low- density lipoprotein cholesterol; and Lp(a), lipoprotein (a). Reproduced with permission from Grundy et al.S4.3-1 Copyright 2018, American Heart Association, Inc., and American College of Cardiology Foundation. CLINICAL STATEMENTS AND GUIDELINES group, the 10-year risk of hard ASCVD was 8.7%, and the risk of the expanded ASCVD end- point that included coronary revascularization After 5.6 years, those assigned to rosuvastatin 10 mg per day showed significant absolute risk reduction in both co-primary end- points, with an acceptable safety record. By com- parison, after a median follow-up of 1.9 years, those assigned to a high-intensity statin dose of rosuvastatin in the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) RCT achieved greater LDL-C lowering and greater reductions in ASCVD This corroborates meta-analyses demonstrating that in those at risk, net benefit of LDL-C lowering therapy is greater with greater reductions in LDL-C.S4.3-2,S4.3-10 2. If in the context of a risk discussion, maximal ASCVD risk reduction is desired, it is reasonable to use a high-intensity statin to lower LDL-C by 50%. This provides increased benefit, espe- cially when 10-year ASCVD risk is 20%. JUPITER enrolled men 50 years of age and women 60 years of age with high-sensitivity C-reactive pro- tein values 2.0 mg/L and LDL-C <130 mg/dL. 